Example: air traffic controller

Guideline for good clinical practice E6(R2)

1 23 July 2015. 2 EMA/CHMP/ICH/135/1995. 3 Committee for Human Medicinal Products 4 Guideline for good clinical practice E6(R2). 5 Step 2b Adopted by CHMP for release for consultation 23 July 2015. Start of public consultation 4 August 2015. End of consultation (deadline for comments) 3 February 2016. 6. 7. Comments should be provided using this template. The completed comments form should be sent to 8. 9. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website An agency of the European Union European Medicines Agency, 2015.

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November

Tags:

  Guidelines, Good, Practices, Clinical, Good clinical practice e6

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of Guideline for good clinical practice E6(R2)

1 1 23 July 2015. 2 EMA/CHMP/ICH/135/1995. 3 Committee for Human Medicinal Products 4 Guideline for good clinical practice E6(R2). 5 Step 2b Adopted by CHMP for release for consultation 23 July 2015. Start of public consultation 4 August 2015. End of consultation (deadline for comments) 3 February 2016. 6. 7. Comments should be provided using this template. The completed comments form should be sent to 8. 9. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website An agency of the European Union European Medicines Agency, 2015.

2 Reproduction is authorised provided the source is acknowledged. 10 Document History 11. New First Codification History Date Codification November 2005. E6 Approval by the CPMP under Step 3 and release for May 1995 E6. public consultation. E6 Approval by the CPMP under Step 4 and released for July 1996 E6. information. 12 Step 5 corrected version E6 Approval by the CPMP of Post-Step 4 editorial July 2002 E6(R1). corrections. 13 Current E6(R2) Addendum Step 2 version Code History Date E6 Approval by the Steering Committee under Step 2 and release for 11 June public consultation.

3 2015. Integrated Addendum to ICH E6(R1) document. Changes are integrated directly into the following sections of the parental Guideline : Introduction, , , , , , , , , , , , , , , , , , , , , , , , 14. Guideline for good clinical practice E6(R2). EMA/CHMP/ICH/135/1995 Page 2/75. 15 Guideline for good clinical practice E6(R2). 16 Table of contents 17 Introduction .. 7. 18 1. Glossary .. 8. 19 Adverse Drug Reaction (ADR) .. 8. 20 Adverse Event (AE) .. 8. 21 Amendment (to the protocol) .. 8. 22 Applicable regulatory requirement(s) .. 8. 23 Approval (in relation to institutional review boards).

4 8. 24 Audit .. 8. 25 Audit certificate .. 8. 26 Audit report .. 9. 27 Audit trail .. 9. 28 Blinding/masking .. 9. 29 Case Report Form (CRF) .. 9. 30 clinical trial/study .. 9. 31 clinical trial/study report .. 9. 32 Comparator (Product) .. 9. 33 Compliance (in relation to trials) .. 10. 34 Confidentiality .. 10. 35 Contract .. 10. 36 Coordinating committee .. 10. 37 Coordinating investigator .. 10. 38 Contract Research Organization (CRO) .. 10. 39 Direct 10. 40 Documentation .. 10. 41 Essential documents .. 10. 42 good clinical practice (GCP) .. 11. 43 Independent Data-Monitoring Committee (IDMC) (data and safety monitoring 44 board, monitoring committee, data monitoring committee).

5 11. 45 Impartial witness .. 11. 46 Independent Ethics Committee (IEC) .. 11. 47 Informed consent .. 11. 48 Inspection .. 11. 49 Institution (medical) .. 11. 50 Institutional Review Board (IRB).. 12. 51 Interim clinical trial/study report .. 12. 52 Investigational product .. 12. 53 Investigator .. 12. 54 Investigator / institution .. 12. 55 Investigator's brochure .. 12. 56 Legally acceptable representative .. 12. 57 Monitoring .. 12. Guideline for good clinical practice E6(R2). EMA/CHMP/ICH/135/1995 Page 3/75. 58 Monitoring report .. 13. 59 Multicentre trial .. 13. 60 Nonclinical study.

6 13. 61 Opinion (in relation to independent ethics committee) .. 13. 62 Original medical 13. 63 Protocol .. 13. 64 Protocol amendment .. 13. 65 Quality Assurance (QA) .. 13. 66 Quality Control (QC) .. 13. 67 Randomization .. 14. 68 Regulatory authorities .. 14. 69 Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR). 14. 70 Source data .. 14. 71 Source documents .. 14. 72 Sponsor .. 14. 73 Sponsor-Investigator .. 14. 74 Standard Operating Procedures (SOPs) .. 15. 75 Subinvestigator .. 15. 76 Subject/trial 15. 77 Subject identification code .. 15. 78 Trial site.

7 15. 79 Unexpected adverse drug reaction .. 15. 80 Vulnerable 15. 81 Well-being (of the trial subjects) .. 16. 82 2. The principles of ICH GCP .. 17. 83 3. Institutional Review Board / Independent Ethics Committee (IRB/IEC). 84 .. 19. 85 Responsibilities .. 19. 86 Composition, Functions and Operations .. 20. 87 Procedures .. 21. 88 Records .. 22. 89 4. Investigator .. 23. 90 Investigator's Qualifications and Agreements .. 23. 91 Adequate Resources .. 23. 92 Medical Care of Trial Subjects .. 24. 93 Communication with IRB/IEC .. 24. 94 Compliance with Protocol .. 25. 95 Investigational Product(s).

8 26. 96 Randomization Procedures and Unblinding .. 26. 97 Informed Consent of Trial Subjects .. 27. 98 Records and Reports .. 30. 99 Progress Reports .. 31. 100 Safety Reporting .. 32. 101 Premature Termination or Suspension of a 32. Guideline for good clinical practice E6(R2). EMA/CHMP/ICH/135/1995 Page 4/75. 102 Final Report(s) by Investigator .. 33. 103 5. Sponsor .. 34. 104 Quality management .. 34. 105 Quality assurance and quality control .. 35. 106 Contract Research Organization (CRO) .. 36. 107 Medical expertise .. 36. 108 Trial 36. 109 Trial management, data handling, and record keeping.

9 37. 110 Investigator 39. 111 Allocation of responsibilities .. 39. 112 Compensation to subjects and investigators .. 39. 113 Financing .. 40. 114 Notification/submission to regulatory authority(ies) .. 40. 115 Confirmation of review by IRB/IEC .. 40. 116 The sponsor should obtain from the investigator/institution: .. 40. 117 Information on investigational product(s) .. 41. 118 Manufacturing, packaging, labelling, and coding investigational product(s) .. 41. 119 Supplying and handling investigational product(s) .. 42. 120 Record access .. 43. 121 Safety information .. 43. 122 Adverse drug reaction reporting.

10 43. 123 Monitoring .. 44. 124 Audit .. 47. 125 Noncompliance .. 48. 126 Premature termination or suspension of a trial .. 48. 127 clinical trial/study reports .. 48. 128 Multicentre trials .. 49. 129 6. clinical trial protocol and protocol amendment(s).. 50. 130 General Information .. 50. 131 Background Information .. 50. 132 Trial objectives and purpose .. 51. 133 Trial 51. 134 Selection and withdrawal of 52. 135 Treatment of 53. 136 Assessment of Efficacy .. 53. 137 Assessment of 53. 138 Statistics .. 54. 139 Direct access to source data/documents .. 54. 140 Quality control and quality assurance.


Related search queries